Evidence map›Paper›PMID 40692637›Full record

ArticleFuture healthcare journal2025

The NHS and the pharmaceutical industry: High risk of harmful interactions.

Margaret McCartney

Abstract read
In one paragraph

Article in Future healthcare journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Margaret McCartneyUniversity of St Andrews, St Andrews, Fife, Scotland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pharmaceutical industry has been responsible for many interventions of great benefit to patients. However, great harm to patients and healthcare systems have been created through conflicts of interest, when the behaviours of individual doctors and healthcare systems have been compromised and patient harm has resulted. The interests of the pharmaceutical industry and the NHS cannot be assumed to overlap. This means that medical decision making should be as independent and unbiased as possible. Transparency about conflicts is important, but should be a means to the end it must be part of a system which stops conflicts harming patients and healthcare systems. Given the uncertainty of how the benefits of transparency can be used in practice, it is an imperative that conflicts are avoided, and not just 'managed'.

Indexed as

BiasConflicts of interestEvidence based medicineNHSPharmaceutical industry

Identifiers

PMID40692637
PMCPMC12277477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.